Pricing Log in Create free account
Friday 6 November 2026 Export PHAR’s income statement to Excel — free account

Pharming Group N.V. Sponsored ADR

PHAR Healthcare Biotechnology

Pharming Group N.V. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 26.6% from fiscal 2024.

Revenue
+20.9%
EPS
+190.9%
Free cash flow
+0.42%
Total debt
+1.61%

Quarter to September 2026, against a year earlier

12.32 0.02 +0.16%
Market cap
$870.6M
P/E
34.2×
Fwd P/E
0.0×
Dividend yield
—
F-score
5/9
Altman Z
3.88
Beneish M
−2.78
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 12.09%

Capital & Financial Ratios $m

Size
Market Cap 870.59
Revenue ttm 386.79
Net income ttm 34.33
Free cash flow ttm 34.50
Net debt Q (89.63)
Valuation
P/E 34.22
Forward P/E 0.00
Price / sales 2.23
Forward P/S Powerpack
Price / FCF 25.00
Price / book 2.96
Financial health
Current ratio Q 3.23 (at or above 1.5: strong)
Debt / equity Q 0.34 (at or below 0.5: strong)
Interest coverage Q —
Growth
Revenue growth Q +20.86% (above 0%: growing)
Operating income growth Q +88.61% (above 0%: growing)
EPS, this year +646.00% (at or above 15%: strong)
EPS, next year A −2.05% (below 0%: weak)
Revenue, next year A +1,956.11% (at or above 10%: strong)
EPS, past 5 yrs −41.42% (below 0%: weak)
EPS, next 5 yrs A +136.63% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.0×, against a ten-year median of 2.8×; over the ten years it ranged from −4.2× in 2023 to 44.8× in 2020.
P/E against its own 10 years 2.94%
10-year low 10-year high
P/S against its own 10 years 25.44%
10-year low 10-year high
P/B against its own 10 years 29.13%
10-year low 10-year high
EV/Sales against its own 10 years 23.25%
10-year low 10-year high
EV/FCF against its own 10 years 34.36%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 213 168 180 190
Receivables 46 55 55 75
Inventory 57 56 65 58
Other — — — —
316 278 299 322
2023 2024 2025 Q'26
Payables 73 67 106 90
ST’ Debt 2 4 5 6
Other — — 1 1
78 74 116 100

Compound Annual Growth %

10y 5y 3y
Sales — 12.13% 22.30%
Cash Flow — (8.14%) 34.55%
Earnings — (40.35%) (40.70%)
Book Value — 8.60% 10.63%

Earnings Trends EPS, adjusted, against the consensus

Sep 2026 Estimate 0.33 Actual 0.30

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Dec 2025 0.15 0.07 Miss by 0.08
Mar 2026 0.05 −0.07 Miss by 0.12
Jun 2026 0.20 0.02 Miss by 0.18
Sep 2026 0.33 0.30 Miss by 0.03
Dec 2026 0.07 — Reports 11 March 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.07) 0.03 0.30 — —
’25 (0.22) 0.06 0.10 0.07 0.04
’24 (0.19) (0.02) (0.02) 0.05 (0.16)
’23 (0.17) (0.02) 0.05 (0.04) (0.15)
’22 0.05 0.02 0.13 (0.02) 0.19
’21 0.13 0.01 0.00 0.00 0.19
’20 0.13 0.01 0.01 0.01 0.58
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 72 90 118 — —
’25 79 93 97 107 376
’24 56 74 75 93 297
’23 43 55 67 81 245
’22 47 49 54 57 206
’21 44 49 52 52 199
’20 54 44 54 63 212
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 2 (10) 32 — —
’25 0 12 32 11 55
’24 (8) (13) 10 9 (2)
’23 (23) (10) 4 12 (17)
’22 1 4 17 5 22
’21 7 9 3 15 38
’20 22 23 65 20 84
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 2 (10) 32 — —
’25 0 12 32 10 54
’24 (8) (13) 9 9 (3)
’23 (23) (10) 3 11 (19)
’22 0 3 16 5 20
’21 4 5 (6) 15 21
’20 15 23 63 17 68
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 17 108 155 189 212 199 206 245 297 376 387 +41.3% — — — —
Gross margin, % 65.73 82.38 80.81 87.37 88.91 89.37 91.46 89.72 88.09 87.90 85.10 +22.2 pt
EBT (18) (103) 1 52 44 23 15 (12) (8) 13 34 n/m
EBT margin, % (110.48) (95.61) 0.63 27.62 20.78 11.60 7.29 (4.90) (2.86) 3.42 8.86 +113.9 pt
Net income (18) 0 29 52 44 23 15 (12) (8) 13 34 n/m
Per share, $
Per share, $ Revenue 0.04 0.22 2.53 3.02 3.33 3.10 3.17 3.73 4.43 5.46 5.53 +72.6%
Earnings (0.04) (0.18) 0.47 0.65 0.58 0.21 0.21 (0.15) (0.16) 0.04 0.36 n/m
Cash flow (0.03) 0.07 0.55 1.19 1.31 0.59 0.35 (0.26) (0.03) 0.79 0.51 n/m
Capex 0.00 0.00 0.00 (0.41) (0.24) (0.26) (0.03) (0.02) (0.01) (0.01) (0.01) n/m
Free cash flow (0.03) 0.07 0.55 0.78 1.07 0.33 0.32 (0.29) (0.04) 0.78 0.49 n/m
Book value 0.07 0.04 1.16 1.87 2.88 3.00 3.15 3.33 3.29 4.02 4.16 +57.0%
Shares, m 415 500 61 63 64 64 65 66 67 69 67 (18.1%)
Valuation, ×
Valuation, × P/E 80.75 80.75 80.75 80.75 77.31 63.00 60.74 0.00 0.00 441.75 34.22 96.6
P/S 52.19 52.19 52.19 52.19 44.99 29.41 3.65 3.08 2.27 3.24 2.23 29.5
P/B 66.90 66.90 66.90 66.90 52.65 30.09 3.69 3.45 3.06 4.39 2.96 36.5
EV/Sales 52.01 52.01 52.01 52.01 44.79 29.25 3.29 2.77 1.99 3.02 2.00 29.3
EV/FCF 57.70 57.70 57.70 57.70 79.60 312.97 45.55 (34.00) (184.03) 21.04 22.40 47.2
Cash, $m
Cash, $m Operating cash flow (11) 37 34 74 84 38 22 (17) (2) 55 35 n/m
Capex (2) (7) (4) (25) (15) (17) (2) (1) (1) (1) (1) (8.0%)
Free cash flow (11) 37 34 49 68 21 20 (19) (3) 54 35 n/m
Balance, $m
Balance, $m Working capital 11 33 38 5 186 203 218 238 205 184 222 +36.2%
Net debt 37 28 (8) (18) (54) (51) (74) (75) (85) (82) (90) n/m
Shareholders’ equity 29 19 71 117 183 193 205 219 221 277 291 +28.5%
Returns, %
Returns, % ROA (11.06) (137.67) 15.12 16.14 11.20 3.92 3.32 (2.37) (2.74) 0.63 5.00 +11.7 pt
ROIC 0.00 0.00 0.00 43.09 36.93 5.98 8.73 (2.34) (3.97) 8.27 10.07 +8.3 pt
ROE (76.40) (380.21) 63.57 43.08 25.11 8.50 6.88 (4.98) (5.38) 1.14 8.73 +77.5 pt
People
People Employees — — — 258 229 277 332 382 404 409 — +8.0%
Revenue/emp, $m 0.00 0.00 0.00 0.73 0.93 0.72 0.62 0.64 0.74 0.92 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 2 Nov 2026

Pharming Group N.V. Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
JBIO Jade Biosciences, Inc. $896.7M — (loss-making) — — n/m −115.11% (below 0%: shrinking) 0.00% 0.00% Compare
CTY City Therapeutics, Inc $882.9M — — — — — — — Compare
ORIC Oric Pharmaceuticals, Inc. $880.0M — (loss-making) — — n/m −3.42% (below 0%: shrinking) 0.00% 0.00% Compare
GLUE Monte Rosa Therapeutics, Inc. $874.5M — (loss-making) — (loss-making) +325.80% (above 0%: growing) n/m −142.63% (below 0%: shrinking) 100.00% (3.57%) Compare
PHAR Pharming Group N.V. Sponsored ADR $870.6M 34.2× — (loss-making) +20.86% (above 0%: growing) +190.91% (above 0%: growing) +0.42% (above 0%: growing) 86.90% 25.34%
IVA Inventiva S.A. Sponsored ADR $867.9M — (loss-making) — (loss-making) −10.77% (below 0%: shrinking) n/m −20,989.22% (below 0%: shrinking) 0.00% 0.00% Compare
LTGO Latigo Biotherapeutics Inc $862.6M — — — n/m — — 0.00% Compare
ANRO Alto Neuroscience, Inc. $858.2M — (loss-making) — — n/m −43.41% (below 0%: shrinking) — 0.00% Compare
RIGL Rigel Pharmaceuticals, Inc. $853.9M 2.4× 16.4× +16.45% (above 0%: growing) −54.84% (below 0%: shrinking) +43.90% (above 0%: growing) 86.67% 21.15% Compare
Median of peers $871.2M — — +16.45% — −79.26% 0.00% 0.00%

All 621 Biotechnology stocks →

Pharming Group N.V. Sponsored ADR (PHAR) Latest News

6 Nov

Impact 3 · · GlobeNewswire

4 Nov

Impact 3 · · The Motley Fool

28 Oct

Impact 4 · · Simply Wall St.

27 Oct

Impact 4 · · The Motley Fool transcript
Impact 4 · · MarketBeat
Impact 4 · · GlobeNewswire

22 Oct

Impact 4 · · GlobeNewswire

14 Oct

Impact 4 · · GlobeNewswire

29 Sep

Impact 3 · · GlobeNewswire

25 Sep

Impact 4 ·

22 Sep

Impact 4 ·

16 Sep

Impact 3 ·

11 Sep

Impact 4 ·

13 Aug

Impact 4 ·

2 Aug

Impact 4 ·

30 Jul

Impact 4 ·
Impact 4 ·
Impact 3 · · MarketBeat transcript

27 Jun

Impact 3 ·

4 Jun

Impact 4 ·

22 May

Impact 4 · · GlobeNewswire

14 May

Impact 4 · · Simply Wall St.

11 May

Impact 3 · · Simply Wall St.

8 May

Impact 4 · · MarketBeat

7 May

Impact 4 · · GlobeNewswire
Impact 3 · · GlobeNewswire

10 Apr

Impact 3 · · Simply Wall St.

27 Mar

Impact 4 · · GlobeNewswire

25 Mar

Impact 4 · · Simply Wall St.
Impact 3 · · MarketBeat
stockrow.com/PHAR · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com